NCT05411497View on ClinicalTrials.gov

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 20, 2022

Primary Completion Date

August 18, 2027

Study Completion Date

August 18, 2028

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
BIOLOGICAL

Autologous MUC1-activated T-cells

Given IV

DRUG

Cyclophosphamide

Given IV

Trial Locations (2)

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05411497 - Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter